August 2018

Deepbridge are pleased to report that Glyconics, which is part of the Deepbridge Life Sciences SEIS portfolio, have signed a hardware partner agreement with Spectrolytic, a leading developer in infared (IR) spectrometers.

The biopharmaceutical company Almac Discovery - part of the contract development and manufacturing organisation (CDMO) Almac Group -and Elasmogen, a University of Aberdeen spin-out firm and part of the Deepbridge Life Sciences EIS portfolio, have been awarded a £2m grant from Innovate UK.